Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals.
Moldt B, Günthard HF, Workowski KA, Little SJ, Eron JJ, Overton ET, Lehmann C, Rokx C, Kozal MJ, Gandhi RT, Braun DL, Parvangada A, Li J, Martin R, Selzer L, Cox S, Margot N, Liu H, Slamowitz D, Makadzange T, Collins SE, Geleziunas R, Callebaut C. Moldt B, et al. Among authors: geleziunas r. AIDS. 2022 Feb 1;36(2):205-214. doi: 10.1097/QAD.0000000000003088. AIDS. 2022. PMID: 34586088
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.
Moldt B, Parvangada A, Martin R, Pace C, Balakrishnan M, Thomsen ND, E Collins S, Kuster H, Braun DL, Günthard HF, Geleziunas R, Callebaut C. Moldt B, et al. Among authors: geleziunas r. J Acquir Immune Defic Syndr. 2021 Sep 1;88(1):61-69. doi: 10.1097/QAI.0000000000002722. J Acquir Immune Defic Syndr. 2021. PMID: 34397744
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. Julg B, et al. Among authors: geleziunas r. Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Lancet HIV. 2019. PMID: 30885693 Free PMC article.
HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.
Moldt B, Chandrashekar A, Borducchi EN, Nkolola JP, Stephenson H, Nagel M, Hung M, Goldsmith J, Pace CS, Carr B, Thomsen ND, Blair WS, Geleziunas R, Barouch DH. Moldt B, et al. Among authors: geleziunas r. PLoS Pathog. 2022 Apr 22;18(4):e1010467. doi: 10.1371/journal.ppat.1010467. eCollection 2022 Apr. PLoS Pathog. 2022. PMID: 35452496 Free PMC article.
Blood biomarkers of expressed and inducible HIV-1.
Cillo AR, Hong F, Tsai A, Irrinki A, Kaur J, Sloan DD, Follen M, Geleziunas R, Cihlar T, Win SS, Murry JP, Mellors JW. Cillo AR, et al. Among authors: geleziunas r. AIDS. 2018 Mar 27;32(6):699-708. doi: 10.1097/QAD.0000000000001748. AIDS. 2018. PMID: 29334544 Free PMC article.
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, Cai Y, Wallin JJ, Zhang L, Humeniuk R, Begley R, Geleziunas R, Mellors J, Wrin T, Jones N, Milush J, Ferre AL, Shacklett BL, Laird GM, Moldt B, Vendrame E, Brainard DM, Ramgopal M, Deeks SG. SenGupta D, et al. Among authors: geleziunas r. Sci Transl Med. 2021 Jun 23;13(599):eabg3071. doi: 10.1126/scitranslmed.abg3071. Sci Transl Med. 2021. PMID: 34162752 Clinical Trial.
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges.
Vidal SJ, Bekerman E, Hansen D, Lu B, Wang K, Mwangi J, Rowe W, Campigotto F, Zheng J, Kato D, Chandrashekar A, Barrett J, Patel S, Wan H, Anioke T, Mercado NB, Nkolola JP, Ferguson MJ, Rinaldi WJ, Callebaut C, Blair W, Cihlar T, Geleziunas R, Yant SR, Barouch DH. Vidal SJ, et al. Among authors: geleziunas r. Nature. 2022 Jan;601(7894):612-616. doi: 10.1038/s41586-021-04279-4. Epub 2021 Dec 7. Nature. 2022. PMID: 34875675 Free PMC article.
TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption.
Hsu DC, Schuetz A, Imerbsin R, Silsorn D, Pegu A, Inthawong D, Sopanaporn J, Visudhiphan P, Chuenarom W, Keawboon B, Shi W, Robb ML, Mascola JR, Geleziunas R, Koup RA, Barouch DH, Michael NL, Vasan S. Hsu DC, et al. Among authors: geleziunas r. PLoS Pathog. 2021 Feb 18;17(2):e1009339. doi: 10.1371/journal.ppat.1009339. eCollection 2021 Feb. PLoS Pathog. 2021. PMID: 33600506 Free PMC article.
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.
Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, Broge T, Abbink P, Mercado NB, Chandrashekar A, Jetton D, Peter L, McMahan K, Moseley ET, Bekerman E, Hesselgesser J, Li W, Lewis MG, Alter G, Geleziunas R, Barouch DH. Borducchi EN, et al. Among authors: geleziunas r. Nature. 2018 Nov;563(7731):360-364. doi: 10.1038/s41586-018-0600-6. Epub 2018 Oct 3. Nature. 2018. PMID: 30283138 Free PMC article.
105 results